FDA approves Theravance's Vibativ for nosocomial pneumonia

Theravance obtained the FDA's approval to market its injectable antibiotic Vibativ as a treatment for hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. The once-daily antibiotic, however, should be prescribed only when alternative treatments are not suitable, the FDA said. Vibativ was previously approved for treatment of complicated skin and skin-structure infections.

View Full Article in:

American City Business Journals · Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX